Natural endogenous ligands have not yet been identified, but chemical ligands/activators such as thiazolidinediones (for example, rosiglitazone) are potent activators of PPARγ and have been used in a clinical setting for the treatment of insulin resistance [46]. This evidence concerns the gene PPARG and Insulin resistance.